Related Experiment Video

Updated: Mar 24, 2026

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.7K

NR4A1 Antagonists Inhibit β1-Integrin-Dependent Breast Cancer Cell Migration

Erik Hedrick1, Syng-Ook Lee2, Ravi Doddapaneni3

  • 1Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas, USA.

Molecular and Cellular Biology
|March 2, 2016
PubMed

Insights

Nuclear receptor 4A1 (NR4A1) drives breast cancer metastasis by regulating integrin expression. NR4A1 antagonists offer a novel therapeutic strategy by inhibiting both β1- and β3-integrin, unlike other treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Nuclear receptor 4A1 (NR4A1) overexpression correlates with poor prognosis in breast cancer.
  • NR4A1 influences breast cancer metastasis through transforming growth factor β (TGF-β) signaling pathways.

Purpose of the Study:

  • To investigate the role of NR4A1 in breast cancer cell migration.
  • To evaluate the efficacy of NR4A1 antagonists in inhibiting metastasis.

Main Methods:

  • RNA interference studies were performed on aggressive breast cancer cell lines (SKBR3, MDA-MB-231).
  • NR4A1 antagonists, DIM-C-pPhOH and DIM-C-pPhCO2Me, were used to inhibit NR4A1 activity.
  • Gene expression of β1- and β3-integrins was analyzed.

Main Results:

  • NR4A1 regulates β1-integrin gene expression, controlling basal breast cancer cell migration independently of TGF-β.
  • NR4A1 antagonists inhibit TGF-β-induced migration by blocking NR4A1 nuclear export.
  • NR4A1 antagonists suppress both β1- and β3-integrin expression, unlike other inhibitors.

Conclusions:

  • NR4A1 is a key regulator of breast cancer cell migration and metastasis.
  • NR4A1 antagonists represent a novel therapeutic approach targeting integrin expression for breast cancer treatment.
  • Inhibition of both β1- and β3-integrin by NR4A1 antagonists offers a unique strategy against metastasis.

More Related Videos

Quantification of Breast Cancer Cell Invasiveness Using a Three-dimensional 3D Model08:08

Quantification of Breast Cancer Cell Invasiveness Using a Three-dimensional 3D Model

Published on: June 11, 2014

16.5K
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.6K

Related Concept Videos

Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.7K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
735
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.8K
Cell Polarization by Rho Proteins01:21

Cell Polarization by Rho Proteins

Cell polarity is the asymmetric distribution of cellular and membrane components, making one side of the cell different from the other. This polarity is essential to many processes such as embryogenesis, axon migration, glucose transport across epithelial cells, and directional cell migration. A migrating cell responds to intracellular or extracellular signals via molecular cascades that reorganize the actin cytoskeleton to establish this polarity. In these cells, the Rho family proteins Cdc42,...
4.0K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K